10x Genomics, Inc. TXG

What this company does

Since launching its first product in mid-2015 through December 31, 2025, it had sold 8,046 instruments to researchers around the world, including academic and translational researchers and biopharmaceutical companies. It sells its products in over 50 countries, primarily through its own direct sales force in North America and certain regions of Europe, and through third-party distributors in certain regions of Asia, Europe, Oceania, North America, South America, the Middle East and Africa. As of December 31, 2025, it employed a total of 1,178 individuals, 822 of whom were employed in the United States and 356 outside the United States, including 332 in research and development, 473 in sales, marketing and support, 185 in general and administrative and 188 in manufacturing. For the years ended December 31, 2025 and 2024, no single customer, including distributors, represented greater than 10% of its business. Its single cell portfolio, powered by its Chromium platform, includes microfluidic chips and related consumables and its Chromium X Series and legacy Chromium instruments, which serve as reagent delivery systems partitioning samples into individual components that can exceed one million. Its spatial portfolio is powered by its Visium and Xenium platforms, combining histology and genomics. It was incorporated in the State of Delaware on July 2, 2012 under the name Avante Biosystems, Inc., and changed its name to 10X Technologies, Inc. in September 2012 and to 10x Genomics, Inc. in November 2014.

Written from the business description in 10x Genomics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 13 February 2026. Every sentence was checked against that document before publication.